BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35777239)

  • 1. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
    Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
    Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
    Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
    Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
    Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Langenbach MC; Vogl TJ; Said G; Scholtz JE; Hammerstingl R; Gruber-Rouh T
    Cancer Biother Radiopharm; 2024 Apr; 39(3):196-202. PubMed ID: 33481646
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
    Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
    Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.
    Chapiro J; Duran R; Lin M; Mungo B; Schlachter T; Schernthaner R; Gorodetski B; Wang Z; Geschwind JF
    Eur J Radiol; 2015 Mar; 84(3):424-430. PubMed ID: 25542065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
    Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
    Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer.
    Stark S; Wang C; Savic LJ; Letzen B; Schobert I; Miszczuk M; Murali N; Oestmann P; Gebauer B; Lin M; Duncan J; Schlachter T; Chapiro J
    Sci Rep; 2020 Oct; 10(1):18026. PubMed ID: 33093524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Treatment Response of Colorectal Cancer Liver Metastases to Conventional Lipiodol-Based Transarterial Chemoembolization Using Diffusion-Weighted MR Imaging: Value of Pretreatment Apparent Diffusion Coefficients (ADC) and ADC Changes Under Therapy.
    Lahrsow M; Albrecht MH; Bickford MW; Vogl TJ
    Cardiovasc Intervent Radiol; 2017 Jun; 40(6):852-859. PubMed ID: 28357571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization.
    Wu X; Chapiro J; Malhotra A
    J Am Coll Radiol; 2021 Jul; 18(7):927-934. PubMed ID: 33484726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
    Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE.
    Hu B; Zhong BY; Zhang L; Dai C; Li W; Shen J; Huang P; Zhang S; Li Z; Ni CF
    Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1460-1467. PubMed ID: 32500251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis.
    Park C; Gwon DI; Chu HH; Kim JW; Kim JH; Ko GY
    Abdom Radiol (NY); 2021 Aug; 46(8):3729-3737. PubMed ID: 33141259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT.
    Hazhirkarzar B; Tang H; Ghadimi M; Baghdadi A; Motaghi M; Wu Q; Shaghaghi M; Kamel I
    Abdom Radiol (NY); 2021 Oct; 46(10):4610-4618. PubMed ID: 34089068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation.
    Gordon AC; Lewandowski RJ; Li W; Zhong X; Kannengiesser SAR; Miller FH; Salem R; Rilling WS; Larson AC; White SB
    Radiol Imaging Cancer; 2023 May; 5(3):e220019. PubMed ID: 37233207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.